Bastion Asset Management Inc. Buys 135,294 Shares of Certara, Inc. $CERT

Bastion Asset Management Inc. boosted its position in Certara, Inc. (NASDAQ:CERT) by 242.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 191,105 shares of the company’s stock after purchasing an additional 135,294 shares during the quarter. Bastion Asset Management Inc.’s holdings in Certara were worth $1,137,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of CERT. Northwestern Mutual Wealth Management Co. increased its stake in Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after acquiring an additional 2,870 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares during the last quarter. Chicago Partners Investment Group LLC purchased a new stake in Certara in the first quarter valued at approximately $78,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Certara in the second quarter valued at approximately $83,000. 73.96% of the stock is owned by institutional investors.

Certara Trading Up 3.1%

CERT opened at $7.28 on Friday. Certara, Inc. has a one year low of $4.45 and a one year high of $13.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The business has a 50 day simple moving average of $5.76 and a two-hundred day simple moving average of $6.71. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -72.80 and a beta of 1.46.

Certara (NASDAQ:CERT) last announced its earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The business had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. During the same quarter in the prior year, the company earned $0.14 EPS. Certara’s revenue was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Analysts predict that Certara, Inc. will post 0.24 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on CERT. KeyCorp dropped their price target on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Monday, April 13th. BMO Capital Markets decreased their price objective on Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. Robert W. Baird cut their target price on Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th. Morgan Stanley reduced their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.85.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.